KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Leases (2020 - 2025)

Aurinia Pharmaceuticals' Operating Leases history spans 6 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 14.68% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, down 14.68%, while the annual FY2025 figure was $4.9 million, 14.68% down from the prior year.
  • Operating Leases reached $4.9 million in Q4 2025 per AUPH's latest filing, down from $5.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $8.9 million in Q3 2021 to a low of $4.9 million in Q4 2025.
  • Average Operating Leases over 5 years is $7.0 million, with a median of $7.1 million recorded in 2022.
  • Peak YoY movement for Operating Leases: surged 53.12% in 2021, then decreased 24.53% in 2025.
  • A 5-year view of Operating Leases shows it stood at $7.7 million in 2021, then decreased by 6.88% to $7.2 million in 2022, then decreased by 8.7% to $6.5 million in 2023, then decreased by 12.05% to $5.7 million in 2024, then fell by 14.68% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Operating Leases are $4.9 million (Q4 2025), $5.1 million (Q3 2025), and $6.4 million (Q2 2025).